weekeepeedia

IP属地:未知
    • weekeepeediaweekeepeedia
      ·2021-12-17
      I would add also the payment networks. Esp $MasterCard(MA)$

      3 No-Brainer Stocks To Buy in a Market Correction

      These tech stocks have economic moats and growth catalysts, but they're a bit expensive right now.
      3 No-Brainer Stocks To Buy in a Market Correction
      203评论
      举报
    • weekeepeediaweekeepeedia
      ·2021-11-24
      $MasterCard(MA)$Inflation is a positive for MA and V. When goods and services are priced higher, they make more $ as their revenue is a percentage of consumer spend. If consumers break down to make smaller but more frequent purchases, they also benefit from transaction fees. DYODD
      4792
      举报
    • weekeepeediaweekeepeedia
      ·2021-10-25
      $RAFFLES MEDICAL GROUP LTD(BSL.SI)$Good time to accumulate?CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price fro
      1,0541
      举报
    • weekeepeediaweekeepeedia
      ·2021-10-25
      $RAFFLES MEDICAL GROUP LTD(BSL.SI)$Good time to accumulate?CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price fro
      7874
      举报
    • weekeepeediaweekeepeedia
      ·2021-10-18
      9201
      举报
     
     
     
     

    热议股票